Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Parkinson’s disease and related disorders

Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment.

Ryosuke Kojima; Daniel Bojar; Giorgio Rizzi; Ghislaine Charpin-El Hamri; Marie Daoud El-Baba; Pratik Saxena; Simon Ausländer; Kelly R Tan; Martin Fussenegger; Martin Fussenegger

Originally published in Nature communications · 2018-04-03

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Exosomes are cell-derived nanovesicles (50-150 nm), which mediate intercellular communication, and are candidate therapeutic agents. However, inefficiency of exosomal message transfer, such as mRNA, and lack of methods to create designer exosomes have hampered their development into therapeutic interventions. Here, we report a set of EXOsomal transfer into cells (EXOtic) devices that enable efficient, customizable production of designer exosomes in engineered mammalian cells. These genetically encoded devices in exosome producer cells enhance exosome production, specific mRNA packaging, and delivery of the mRNA into the cytosol of target cells, enabling efficient cell-to-cell communication without the need to concentrate exosomes. Further, engineered producer cells implanted in living mice could consistently deliver cargo mRNA to the brain. Therapeutic catalase mRNA delivery by designer exosomes attenuated neurotoxicity and neuroinflammation in in vitro and in vivo models of Parkinson's disease, indicating the potential usefulness of the EXOtic devices for RNA delivery-based therapeutic applications.

Discussion

Inspired by synthetic biology, we have successfully developed EXOtic devices enabling efficient customizable production of designer exosomes. Moreover, we showed a potential application of the exosome producer cells equipped with the EXOtic devices in the treatment of Parkinson’s disease by the delivery of catalase mRNA into the brain.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?